From our analysis, we propose: (1) MDS-h and MDS, NOS with SLD patients had better outcomes; (2) Patients with ≥5% blasts in PB show outcomes akin to MDS/AML, worse than do those with lower blasts; (3) When patients have a PB blast percentage ≥10%, not only multi-hit but also single-hit TP53 mutations confer detrimental effects. The gene discussed is TP53; the disease is myelodysplastic syndrome.